KRAS-targeting Pill Shows Promise Against Pancreatic Cancer
TL;DR Summary
A new oral drug, daraxonrasib, targets the KRAS gene in pancreatic ductal adenocarcinoma, showing in early Phase 1/2 data a median overall survival around 13 months and tumor shrinkage in some patients, nearly doubling survival compared with standard chemotherapy; however, about 30% experience severe side effects, and questions about access and cost remain as full Phase 3 results near disclosure at ASCO.
- Pancreatic cancer is deadly and difficult to treat. A new pill could change that PBS
- How scientists found a weakness in one of the deadliest ‘undruggable’ cancers The Washington Post
- Patients, doctors hail 'revolutionary' new drug for pancreatic cancer Chicago Sun-Times
- Daraxonrasib Demand Grows Amid Expanded Access Rollout in Metastatic PDAC Targeted Oncology
- Chemo Selection in Metastatic Pancreatic Cancer Continues to Evolve With KRAS-Targeted Therapies on the Horizon OncLive
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
7 min
vs 8 min read
Condensed
96%
1,485 → 62 words
Want the full story? Read the original article
Read on PBS